Literature DB >> 27046514

Feasibility of assessing pulmonary blood volume using C-arm CT during transpulmonary chemoperfusion and chemoembolization in primary and secondary lung tumours.

Thomas J Vogl1, Nour-Eldin A Nour-Eldin1,2, Nagy N N Naguib1,3, Thomas Lehnert1, Hanns Ackermann4, Renate Hammerstingl1, Marcus Hezel1.   

Abstract

OBJECTIVE: Assessment of parenchymal blood volume (PBV) of primary and secondary pulmonary malignancies by using a C-arm CT, regarding its role in detecting early functional response to transpulmonary chemoembolization (TPCE) and clinical practicability.
METHODS: 21 patients with a mean age of 56.77 years, who were assigned to TPCE during their palliative treatment, were included. PBV and the diameter of tumours were analyzed. PBV maps were calculated from three-dimensional CT-angiographic (3D-CTA) data sets. Imaging was performed on a flat detector, C-arm CT. Groups of response were classified according to the criteria of the response evaluation criteria in solid tumours. Statistically significant differences were determined and Pearson's regression analysis correlated PBV and diameter as parameters of response to treatment.
RESULTS: During 4.91 sessions, median diameter increased 18.18% (p > 0.05) and PBV reduced 39.62% (p > 0.05). Functional and imaging response per tumour was statistical significantly different (p ≤ 0.05). Correlation coefficient was r = 0.058. 2/41 tumours showed partial response; 31/41 tumours showed stable disease; and 8/41 tumours showed progressive disease. The highest pre-treatment PBV values were measured in decreasing tumours (206.93 ml l(-1)), and the lowest values were measured in increasing tumours (60.17 ml l(-1); p > 0.05). The lowest values were also measured in lung cancer (53.02 ml l(-1)) that was significantly different to uterine leiomyosarcoma (103.31 ml l(-1)) and renal cell cancer (113.14 ml l(-1); p ≤ 0.05).
CONCLUSION: Assessment of PBV maps by using 3D-CTA image data is feasible in the clinical routine. PBV shows a stronger response to TPCE treatment than measurement in diameter and should be considered as a response parameter for early detection. ADVANCES IN KNOWLEDGE: Assessment of PBV using C-arm CT during TPCE is a feasible technique. Assessment of PBV might be useful in assessing response to treatment.

Entities:  

Mesh:

Year:  2016        PMID: 27046514      PMCID: PMC5258138          DOI: 10.1259/bjr.20150244

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  17 in total

Review 1.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

Authors:  David G Pfister; David H Johnson; Christopher G Azzoli; William Sause; Thomas J Smith; Sherman Baker; Jemi Olak; Diane Stover; John R Strawn; Andrew T Turrisi; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2003-12-22       Impact factor: 44.544

Review 2.  Tumor response assessments with diffusion and perfusion MRI.

Authors:  Sonia P Li; Anwar R Padhani
Journal:  J Magn Reson Imaging       Date:  2012-04       Impact factor: 4.813

3.  New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy.

Authors:  Mizuki Nishino; David M Jackman; Hiroto Hatabu; Beow Y Yeap; Leigh-Anne Cioffredi; Jeffrey T Yap; Pasi A Jänne; Bruce E Johnson; Annick D Van den Abbeele
Journal:  AJR Am J Roentgenol       Date:  2010-09       Impact factor: 3.959

4.  New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy.

Authors:  Ho Yun Lee; Kyung Soo Lee; Myung-Ju Ahn; Hye Sun Hwang; Ju Won Lee; Keunchil Park; Jin Seok Ahn; Tae Sung Kim; Chin A Yi; Myung Jin Chung
Journal:  Lung Cancer       Date:  2010-11-18       Impact factor: 5.705

5.  Superselective transcatheter arterial chemoembolisation of an unresectable hepatocellular carcinoma using three-dimensional rotational angiography.

Authors:  H Takao; I Doi; T Watanabe
Journal:  Br J Radiol       Date:  2007-05       Impact factor: 3.039

Review 6.  The cellular basis of site-specific tumor metastasis.

Authors:  B R Zetter
Journal:  N Engl J Med       Date:  1990-03-01       Impact factor: 91.245

Review 7.  Interactive three-dimensional volume rendering of spiral CT data: current applications in the thorax.

Authors:  P T Johnson; E K Fishman; J R Duckwall; P S Calhoun; D G Heath
Journal:  Radiographics       Date:  1998 Jan-Feb       Impact factor: 5.333

Review 8.  Lung radiofrequency and microwave ablation: a review of indications, techniques and post-procedural imaging appearances.

Authors:  S L Smith; P E Jennings
Journal:  Br J Radiol       Date:  2014-12-03       Impact factor: 3.039

Review 9.  Radiologic measurements of tumor response to treatment: practical approaches and limitations.

Authors:  Chikako Suzuki; Hans Jacobsson; Thomas Hatschek; Michael R Torkzad; Katarina Bodén; Yvonne Eriksson-Alm; Elisabeth Berg; Hirofumi Fujii; Atsushi Kubo; Lennart Blomqvist
Journal:  Radiographics       Date:  2008 Mar-Apr       Impact factor: 5.333

10.  Transpulmonary chemoembolization (TPCE) as a treatment for unresectable lung metastases.

Authors:  Thomas J Vogl; Thomas Lehnert; Stephan Zangos; Katrin Eichler; Renate Hammerstingl; Huedayi Korkusuz; Sebastian Lindemayr
Journal:  Eur Radiol       Date:  2008-06-14       Impact factor: 5.315

View more
  2 in total

1.  Utilizing flat-panel detector parenchymal blood volume imaging (FD-PBV) for quantitative kidney perfusion analysis during the process of percutaneous transluminal renal angioplasty (PTRA): A case report.

Authors:  Chenyang Qiu; Jiang Shao; Xiu Liu; Bao Liu
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

2.  Drug-eluting beads-transcatheter arterial chemoembolization with or without iodine-125 treatment is effective and tolerable in treating advanced non-small cell lung cancer patients: a pilot study.

Authors:  Zhongwei Zhao; Jianfei Tu; Xiaoxi Fan; Jingjing Song; Fazong Wu; Xihui Ying; Jianting Mao; Jiansong Ji
Journal:  Transl Cancer Res       Date:  2020-05       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.